Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide Acetyl-Ser-Asp-Lys-Pro in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 3, 1999, Pages 982-987

  Junot, Christophe ^a   Nicolet, Laurence ^b   Ezan, Eric ^a   Gonzales, Marie Francoise ^c   Menard, Joel ^b,c   Azizi, Michel ^b  

^a Institut National de la Recherche Agronomique   (France)

^b HÔPITAL BROUSSAIS   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERASPENIDE; TETRAPEPTIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVE SITE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BONE MARROW; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH INHIBITORS; KIDNEY; LUNG; MALE; OLIGOPEPTIDES; PROTEINS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 0032725884     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aidoudi S, Guigon M, Lebeurrier I, Caen JP and Han ZC (1996) In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracil. Br J Hoematol 94:443-448.
2. Azizi M, Ezan E, Nicolet L, Grognet JM and Ménard J (1997) High plasma level of Acetyl-Seryl-Aspartyl-Lysyl-Proline: A new marker of chronic angiotensin-converting enzyme inhibition. Hypertension 30:1015-1019.
3. Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala-J, Gerineau V and Ménard J (1999) Renal and metabolic clearance of AcSDKP during ACE inhibition in humans. Hypertension 33:879-886.
4. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P and Menard J (1996) Acute angiotensin-converting enzyme inhibition increases the plasma levels of the natural stem cell regulator N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. J Clin Invest 97:1-6.
5. Bogden AE, Carde P, de Paillette ED, Moreau JP, Tubiana M and Frindel E (1991) Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapepide inhibitor of hematopoietic stem cell proliferation. Ann NY Acad Sci 628:126-139.
6. Bogden AE, Moreau JP, Gamba-Vitalo C, Deschamp de Paillette E, Tubiana M, Frindel E and Carde P (1998) Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy enhancing the myelopoietic response to GM-CSF. Int J Cancer 76:38-46.
7. + subpopulations in response to growth factors. Blood 82:3307-3314.
8. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
9. Carde P, Chastang C, Goncalves E, Mathieu-Tubiana N, Vuillemin E, Delwail V, Corbion O, Vekhoff A, Isnard F, Ferrero JM, Garria-Giralt E, Gimonet JF, Stoppa AM, Leger-Picherit E, Fadel E, Monpezat JP, Munck JN, Domenge C, Khayat D, Guilhot F, Monnier A, Zittoun R, Brun B, Namer M, Maraninchi D, Deschamp de Paillette E, Guigon M and Najman A (1992) Seraspenide (AcSDKP): Etude en phase I-II d'un inhibiteur de l'hématopoïèse protégeant de la toxicité de monochimiothérapies aracytine et ifosfamide. CR Acad Sci Ser II Life Sci 315:545.
10. Cohen ML and Kurz KD (1982) Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 220:63-69.
11. Comte L, Lorgeot V, Bignon J, Volkov L, Dupuis F, Wdzieczak-Bakala J and Praloran V (1998) In vivo modification of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracile and goralatide. Eur J Clin Invest 28:856-863.
12. Cushman DW, Wang FL, Fung WC, Harvey CM and DeForrest JM (1989) Differentiation of Angiotensin-Converting Enzyme (ACE) Inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 2:294-306.
13. Erdös EG (1990) Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension 16:363-370.
14. Ezan E, Carde P, Le Kerneau J, Ardouin T, Thomas F, Isnard F, Deschamp de Paillette E and Grognet JM (1994) Pharmacokinetics in healthy volunteers and patients of N-AcSDKP (seraspenide), a negative regulator of hematopoiesis. Drug Metab Disp 22:843-848.
15. Grillon C, Rieger K, Bakala J, Schott D, Morgat JL, Hannapel E, Voelter W and Lenfant M (1990) Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAapLysPro a regulator of the hematopoietic system. FEBS Lett 274:30-34.
16. Hirakata H, Onoyama K, Hiseki K, Kumagai H, Fujimi S and Omae T (1984) Worsening of anemia induced by term use of captopril in hemodialysis patients. Am J Nephrol 4:355-360.
17. Junot C, Ménard J, Gonzales MF, Michaud A, Corvol P and Ezan E (1999) In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: Differential inhibition of Acetyl-Ser-Asp-Lys-Pro and angiotensin I hydrolysis. J Pharmacol Exp Ther 289:1257-1261.
18. Khor SP and Mayersohn M (1991) Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations. Drug Metab Dispos 19:478-485.
19. Koike G, Krieger JE and Jacob HJ (1994) Angiotensin converting enzyme and genetic hypertension: cloning of rat cDNAs and characterization of the enzyme. Biochem Biophys Res Commun 198:380-386.
20. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D and Frindel E (1989) Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci USA 86:779-782.
21. Li J, Volkov L, Comte L, Herve P, Praloran V and Charbord P (1997) Production and consumption of the tetrapeptide AcSDKP, a negative regulator of hematopoietic stem cells, by hematopoietic microenvironmental cells. Exp Hematol 25:140-146.
22. Liozon E, Pradelles P, Venot J, Rigaud M, Cransac M, Bordessoule D and Frindel E (1993) Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies. Leukemia 7:808-812.
23. Lombard MN, Sotty D, Wdzieczak-Bakala J and Lenfant M (1990) In vivo effect of the tetrapeptide, Acetyl-N-Ser-Asp-Lys-Pro on the G1-S transition of rat hepatocytes. Cell Tissue Kinet 23:99-103.
24. Masse A, Ramirez LH, Bindoula G, Wdzieczak-Bakala J, Raddassi K, Sainteny F, Deschamp de Paillette E, Mencia-Huerta JM, Potier P and Carde P (1998) The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects mice from doxorubicine-induced toxicity: Improvement in mice survival and protection of bone marrow stem cells and progenitors. Blood 91:441-449.
25. Menant J and Catt KJ (1972) Measurement of renin activity and substrate by radioimmunoassay of angiotensin I. Endocrinology 90:422-430.
26. Ménard J, Guyene TT, Chatellier G, Kleinbloesem CH and Bernadet P (1991) Renin release regulation during acute renin inhibition in normal volunteers. Hypertension 18:257-265.
27. Michaud A, Williams TA, Chauvet MT and Corvol P (1997) Substrate dependence of angiotensin I-converting enzyme Inhibition: Captopril displays a partial selectivity for inhibition of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline hydrolysis compared with that of angiotensin I. Mol Pharmacol 51:1070-1076.
28. Pradelles Ph, Frobert Y, Creminon C, Ivonine H and Frindel E (1991) Distribution of a negative regulator of haemopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues. FEBS Lett 289:171-175.
29. Pradelles Ph, Frobert Y, Creminon C, Liozon E, Massé A and Frindel E (1990) Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analyzed by enzyme immunoassay. Biochem Biophys Res Commun 170:986-993.
30. Rieger KJ, Saez-Servent N, Papet MP, Wdzieczak-Bakala J, Morgat JL, Thierry J, Voelter W and Lenfant M (1993) Involvement of human plasma angiotensin I converting enzyme in the degradation of the haemoregulatory peptide N-Acetyl-Seryl-Aspartyl-Lysyl-Proline. Biochem J 296:1-6.
31. Rhaleb NE, Peng H, Harding P, Yang XP and Carretero OA (1998) AcSDKP, a new inhibitor of cardiac fibroblast proliferation (Abstract). Hypertension 32:609.
32. Robinson S, Lenfant M, Wdzieczak-Bakala J, Melville J and Riches A (1992) The mechanism of action of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell. Cell Prolif 25:623-632.
33. Rousseau A, Michaud A, Chauvet MA, Lenfant M and Corvol P (1995) The hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin converting enzyme. J Biol Chem 270:3656-3661.
34. Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, Ezan E, Genet R, Robinson S, Briscoe T, Melville J and Riches A (1998) Lisinopril, an angiotensin I-converting enzyme inibitor, prevents stem cells into the cell cycle after irradiation in vivo. Exp Hematol 26:1074-1079.
35. Wei L, Clauser E, Alhenc-Gelas F and Corvol P (1992) The two homologous domains of angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 267:13398-13405.
36. Watanabe T, Kesley LS, Yan Y, Brown GS, Jackson JD, Ewel C and Tamadge JE (1996) In vivo protective activity of tetrapeptide AcSDKP combined with granulocyte-colony stimulating factor following sublethal irradiation. Br J Haematol 94: 619-627.
37. Yoshioka T, Iwamoto N,Nitta K, Irie K, Xiao HJ, Ito K and Muraki T (1998) AcSDKP is a novel anti-proliferative peptide for renal fibroblasts. Arch Pharm (Weinbeim) 358 (Suppl 2):742R.